Phase II study of sorafenib in combination with cisplatin and 5-fluorouracil to treat recurrent or metastatic nasopharyngeal carcinoma†

Phase I Trial of Sorafenib in Combination With 5-Fluorouracil/Leucovorin in Advanced Solid Tumors

(2012) Einat Shacham-Shmueli et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Hemorrhagic complications in a phase II study of sunitinib in patients of nasopharyngeal carcinoma who has previously received high-dose radiation

(2011) E. P. Hui et al.   ANNALS OF ONCOLOGY

A Phase II Study of Pazopanib in Asian Patients with Recurrent/Metastatic Nasopharyngeal Carcinoma

(2011) Wan-Teck Lim et al.   CLINICAL CANCER RESEARCH

Addition of bevacizumab to standard chemoradiation for locoregionally advanced nasopharyngeal carcinoma (RTOG 0615): a phase 2 multi-institutional trial

(2011) Nancy Y Lee et al.   LANCET ONCOLOGY

The prevalence and prevention of nasopharyngeal carcinoma in China

(2011) Su-Mei Cao et al.   Chinese Journal of Cancer

Local control, survival, and late toxicities of locally advanced nasopharyngeal carcinoma treated by simultaneous modulated accelerated radiotherapy combined with cisplatin concurrent chemotherapy

(2010) Wei-Wei Xiao et al.   CANCER

Phase III Study of Carboplatin and Paclitaxel Alone or With Sorafenib in Advanced Non–Small-Cell Lung Cancer

(2010) Giorgio Scagliotti et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Evaluation of Sorafenib in Advanced and Metastatic Squamous Cell Carcinoma of the Head and Neck: Southwest Oncology Group Study S0420

(2010) Stephen K. Williamson et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Study of Sorafenib in Combination With Docetaxel and Cisplatin in the Treatment of Metastatic or Advanced Gastric and Gastroesophageal Junction Adenocarcinoma: ECOG 5203

(2010) Weijing Sun et al.   JOURNAL OF CLINICAL ONCOLOGY

Multicenter phase II study of gemcitabine and oxaliplatin in advanced nasopharyngeal carcinoma--correlation with excision repair cross-complementing-1 polymorphisms

(2009) B. B. Y. Ma et al.   ANNALS OF ONCOLOGY

Phase III Trial of Cisplatin Plus Gemcitabine With Either Placebo or Bevacizumab As First-Line Therapy for Nonsquamous Non–Small-Cell Lung Cancer: AVAiL

(2009) Martin Reck et al.   JOURNAL OF CLINICAL ONCOLOGY

Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials

(2009) Youjin Je et al.   LANCET ONCOLOGY

Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study

(2009) Ezra EW Cohen et al.   LANCET ONCOLOGY

Systemic approach to improving treatment outcome in nasopharyngeal carcinoma: Current and future directions

(2008) Brigette B. Y. Ma et al.   CANCER SCIENCE

A Phase I Trial of the Oral, Multikinase Inhibitor Sorafenib in Combination with Carboplatin and Paclitaxel

(2008) K. T. Flaherty et al.   CLINICAL CANCER RESEARCH